Based on the performance of its EP-vCJD assay, Amorfix received and accepted an invitation from the British government to further qualify the specificity of the assay using British blood donor samples to be supplied by the National blood service.
George Adams, CEO of Amorfix, said: “We welcome the continued assistance of the UK government to validate our test for vCJD. The establishment of the test system in the UK will facilitate the testing of fresh blood donor samples as we continue to verify that the assay is suitable for prevalence studies and routine testing of donor blood.”